ES-002 is under clinical development by Elpiscience Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ES-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ES-002 is under development for the treatment of advanced or metastatic solid tumors including pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal adenocarcinoma, gastric cancer. It acts by targeting CD39. The drug candidate is developed based on human-driven immune profiling technology that enables to measure the function and expression of target. It is administered through intravenous route.
Elpiscience Biopharma overview
Elpiscience Biopharma is a clinical-stage biotech company that develops immunotherapies to treat cancer patients. The company’s pipeline products include ES101, ES102, ES104, ES002, ES004, ES005, ES009, ES014, and ES028 antibody. It carries out immune-oncology therapies and approaches, and translational medicine. Elpiscience Biopharma’s products are used for the treatment of solid tumors, including colorectal, pancreatic, gastric cancer, cholangiocarcinoma, and non-small cell lung cancer, among others. The company carries out research and development activities through Immunoshine, AbLego, and Bispecific Macrophage Engager Antibody BiME platforms. It partners with biopharmaceutical companies and academic institutions to accelerate the development of potentially transformative cancer immunotherapies. Elpiscience Biopharma is headquartered in Shanghai, China.
For a complete picture of ES-002’s drug-specific PTSR and LoA scores, buy the report here.